Seventy percent. That's the share of patients on Johnson & Johnson's investigational oral psoriasis pill who rated clear or almost clear at the two-year mark, per long-term extension data circulated by Stock Titan this week.

The figure matters more than its heft suggests. New-systemic psoriasis launches usually come with a 12-week or 52-week headline. A two-year clear/almost-clear rate is rarer to put on a slide. It is the durability point every prescriber circles before switching a stable patient.

What "clear or almost clear" reads as at the desk

That phrasing maps onto the physician-rated endpoints dermatologists already document: sPGA 0/1 and PASI 90/100. Those are the same scores regulators cite in approvals, the same scores payors cite in step-therapy documents, and the same scores you cite when a patient asks why a biologic got denied.

Seven in ten patients keeping that bar at week 104 positions the J&J oral in the same efficacy lane the company's injectable IL-23 drug, Tremfya (guselkumab), has owned in moderate-to-severe plaque psoriasis. J&J is competing as much against its own franchise here as against the rest of the field — and the in-house comparison is the one payors will press hardest on.

What does a durable oral change for psoriasis prescribing?

It reframes the patient pipeline, not just the prescription.

You already know which cases bend a clinic afternoon:

• The needle-averse adult whose coverage capped the biologic menu.
• The young adult who will not commit to an every-8-week self-injection.
• The step-therapy reject where the payor still wants oral-on-topical first.
• The patient whose injection-site reactions have become the chief complaint.
• The adolescent transition where a needle carries a social cost.

A pill that holds efficacy across year one and year two reshapes each of those conversations. It also reframes adherence math — a daily pill versus an every-two-months home or office injection is a different calculus entirely.

The oral psoriasis lane is not empty

J&J enters a chair the TYK2 inhibitor deucravacitinib (Sotyktu, Bristol Myers Squibb) has occupied since 2022. Pfizer and Sun Pharma have readouts aimed at the same seat. A 70%-at-two-years durability story is the harder argument to make against an entrenched oral competitor, and the easier argument to make in front of payor committees.

Positioning will matter as much as the number. A biologic-naïve moderate patient gets a different launch pitch than a biologic-experienced switch candidate. That choice will surface in the label, the field detail, and the formulary placement — and it is the call dermatologists should track most closely.

What this read does not yet contain

The note carried by Stock Titan gives the headline percentage and a thin layer of context. Full efficacy curves, the adverse-event table, patient counts per arm, and discontinuation rates all sit behind J&J's forthcoming data drop and the medical-congress disclosure cycle that follows. Without those, the 70% number reads as durable signal, not durable verdict.

Two years is meaningful on a chronic disease. It is not yet long enough to retire the biologic default.

What to watch next

The peer-reviewed publication and the U.S. payor positioning land within the next twelve months. That window decides whether the J&J oral enters dermatology clinics as a first-line alternative ahead of injectable biologics — or as a complement, saved for the patients injectables do not reach.